Skip to main content

Research Repository

Advanced Search

Effect of smoking status on the efficacy of the SMART regimen in high risk asthma

Pilcher, Janine; Patel, Mitesh; Reddel, Helen K.; Pritchard, Alison; Black, Peter; Shaw, Dominick; Holt, Shaun; Weatherall, Mark; Beasley, Richard

Effect of smoking status on the efficacy of the SMART regimen in high risk asthma Thumbnail


Authors

Janine Pilcher

Mitesh Patel

Helen K. Reddel

Alison Pritchard

Peter Black

Dominick Shaw

Shaun Holt

Mark Weatherall

Richard Beasley



Abstract

Background and objective: The optimal management of people with asthma with a significant smoking history is uncertain. The aim of this study was to determine whether the efficacy/safety profile of single combination inhaled corticosteroid (ICS)/long acting beta-agonist (LABA) inhaler maintenance and reliever therapy is influenced by smoking status.
Methods: We undertook secondary analyses from an open-label 24-week randomized study of 303 high risk adult asthma patients randomized to budesonide/formoterol 200/6-µg-metred dose inhaler for maintenance (two actuations twice daily) and either budesonide/formoterol 200/6-µg-metred dose inhaler one actuation (‘single ICS/LABA maintenance and reliever therapy (SMART)’ regimen) or salbutamol 100 µg 1–2 actuations for symptom relief (‘Standard’ regimen). Smoking status was classified in to three groups, as ‘current’, ‘ex’ or ‘never’, and a smoking/treatment interaction term tested for each outcome variable. The primary outcome variable was number of participants with at least one severe exacerbation.
Results: There were 59 current, 97 ex and 147 never smokers included in the analyses. The smoking status/treatment interaction term was not statistically significant for any of the outcome measures. With adjustment for smoking status, the number of participants with severe exacerbations was lower with the SMART regimen (OR 0.45, 95% CI: 0.26–0.77, P = 0.004; P value for interaction between smoking status and treatment 0.29).
Conclusion: We conclude that the favourable safety/efficacy profile of the SMART regimen applies to patients with high risk asthma, irrespective of smoking status.

Citation

Pilcher, J., Patel, M., Reddel, H. K., Pritchard, A., Black, P., Shaw, D., …Beasley, R. (2016). Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology, 21(5), 858-866. https://doi.org/10.1111/resp.12740

Journal Article Type Article
Acceptance Date Dec 7, 2015
Online Publication Date Feb 21, 2016
Publication Date 2016-07
Deposit Date Jun 15, 2016
Publicly Available Date May 30, 2017
Journal Respirology
Print ISSN 1323-7799
Electronic ISSN 1440-1843
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 21
Issue 5
Pages 858-866
DOI https://doi.org/10.1111/resp.12740
Keywords Adult, asthma, medication adherence, randomized controlled trial, smoking
Public URL https://nottingham-repository.worktribe.com/output/775739
Publisher URL http://onlinelibrary.wiley.com/doi/10.1111/resp.12740/abstract;jsessionid=26F767E582D391F090EE903D072DB882.f02t04
Additional Information This is the peer reviewed version of the following article: Pilcher, J., Patel, M., Reddel, H. K., Pritchard, A., Black, P., Shaw, D., Holt, S., Weatherall, M., and Beasley, R. (2016), Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology, 21: 858–866., which has been published in final form at http:/dx.doi.org/10.1111/resp.12740. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Files





You might also like



Downloadable Citations